Citation

Breggin PR. Int. J. Risk Saf. Med. 2004; 16(4): 247-259.

Copyright

(Copyright © 2004, Elsevier Publishing)

DOI

unavailable

PMID

unavailable

Abstract

[Abstract unavailable]

Language: en

Keywords

United States; Canada; human; violence; insomnia; United Kingdom; depression; aggression; psychosis; suicide attempt; suicidal behavior; clinical trial; risk assessment; review; anorexia; mental disease; prescription; antidepressant agent; behavior disorder; amfebutamone; citalopram; drug induced disease; fluoxetine; fluvoxamine; imipramine; mirtazapine; nefazodone; paroxetine; serotonin uptake inhibitor; sertraline; venlafaxine; automutilation; hazard; impulsiveness; anxiety disorder; panic; hostility; drug safety; drug industry; food and drug administration; psychomotor disorder; risk benefit analysis; medical documentation; akathisia; restlessness; disease exacerbation; irritability; drug screening; drug research; mania; side effect; fluvoxamine maleate; hypomania; escitalopram; agitation; clinical observation; government regulation; mental instability; nervousness; depersonalization; diagnostic and statistical manual of mental disorders; drug labeling; euphoria; stimulant syndrome; stimulation; treatment contraindication